Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.
Several other research firms also recently weighed in on ICPT. Cowen reiterated an “outperform” rating and issued a $232.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. Goldman Sachs Group reiterated a “neutral” rating and issued a $79.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Cantor Fitzgerald reiterated an “underweight” rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Leerink Swann reduced their target price on shares of Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating for the company in a research note on Saturday, September 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $144.13.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $58.20 on Thursday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 12 month low of $54.98 and a 12 month high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company’s revenue was up 697.9% on a year-over-year basis. During the same quarter last year, the company earned ($3.59) earnings per share. research analysts forecast that Intercept Pharmaceuticals will post -13.35 EPS for the current fiscal year.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 2,566 shares of company stock valued at $151,025. 4.50% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its position in Intercept Pharmaceuticals by 100.0% during the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after purchasing an additional 15,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after acquiring an additional 57,149 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its holdings in shares of Intercept Pharmaceuticals by 85.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after acquiring an additional 3,136 shares during the last quarter. Asymmetry Capital Management L.P. bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth approximately $3,580,000. Finally, Senvest Management LLC bought a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter worth approximately $33,883,000. Institutional investors and hedge funds own 73.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/12/07/intercept-pharmaceuticals-icpt-downgraded-by-bidaskclub-to-sell.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.